GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » 3-Year EBITDA Growth Rate

INmune Bio (INmune Bio) 3-Year EBITDA Growth Rate : -17.50% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is INmune Bio 3-Year EBITDA Growth Rate?

INmune Bio's EBITDA per Share for the three months ended in Dec. 2023 was $-0.47.

During the past 3 years, the average EBITDA Per Share Growth Rate was -17.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of INmune Bio was -17.00% per year. The lowest was -256.30% per year. And the median was -17.70% per year.


Competitive Comparison of INmune Bio's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, INmune Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where INmune Bio's 3-Year EBITDA Growth Rate falls into.



INmune Bio 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


INmune Bio  (NAS:INMB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


INmune Bio 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of INmune Bio's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


INmune Bio (INmune Bio) Business Description

Traded in Other Exchanges
N/A
Address
225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Executives
Scott Juda director 325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder director 2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss 10 percent owner, officer: CFO, Treasurer & Secretary C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi director, 10 percent owner, officer: President & CEO 476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell 10 percent owner, officer: Chief Scientific Officer THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei director 10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen director P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini director C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc 10 percent owner 465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski director 241 WEST PALM AVENUE, MONROVIA CA 91016

INmune Bio (INmune Bio) Headlines

From GuruFocus

INmune Bio Inc (INMB) Reports Q3 2023 Financial Results

By GuruFocus Research 11-01-2023